| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | carbohydrate binding | 8.05e-03 | 310 | 9 | 2 | GO:0030246 | |
| MousePheno | increased angiogenesis | 8.67e-05 | 29 | 7 | 2 | MP:0005601 | |
| MousePheno | increased susceptibility to bacterial infection | 2.71e-04 | 283 | 7 | 3 | MP:0002412 | |
| MousePheno | abnormal susceptibility to bacterial infection | 5.49e-04 | 360 | 7 | 3 | MP:0020186 | |
| MousePheno | increased susceptibility to infection | 1.46e-03 | 504 | 7 | 3 | MP:0002406 | |
| Pubmed | A High-Density Map for Navigating the Human Polycomb Complexome. | 2.26e-04 | 495 | 9 | 3 | 27705803 | |
| Interaction | ZNF202 interactions | 8.73e-05 | 32 | 9 | 2 | int:ZNF202 | |
| Interaction | FCN1 interactions | 9.29e-05 | 33 | 9 | 2 | int:FCN1 | |
| Coexpression | GSE9878_CTRL_VS_EBF_TRANSDUCED_PAX5_KO_PRO_BCELL_DN | 3.55e-05 | 200 | 9 | 3 | M6989 | |
| ToppCell | 367C-Lymphocytic-NK_cells-NK_cell_D2|NK_cells / Donor, Lineage, Cell class and subclass (all cells) | 4.23e-04 | 156 | 9 | 2 | 0b3630fd4479291599e1674e87eba6f93877ac3a | |
| ToppCell | 10x5'-bone_marrow-Lymphocytic_B-ABC_aged-B_memory|bone_marrow / Manually curated celltypes from each tissue | 4.68e-04 | 164 | 9 | 2 | 746833f74095c0f25ce76baf1069f1848c231933 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_mem-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 4.96e-04 | 169 | 9 | 2 | e3ec9468141b6456398dca17dd8eeaabd2462710 | |
| ToppCell | facs-Diaphragm-Limb_Muscle-18m-Endothelial-new-cluster|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.02e-04 | 170 | 9 | 2 | 4fb4ce46e4fa2418238e264875209d7ebe844d82 | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Ascending_Vasa_Recta_Endothelial_Cell_prolif|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 5.14e-04 | 172 | 9 | 2 | c056d44e2e130ceccadfcdceb192a7f095d779c8 | |
| ToppCell | facs-Diaphragm-Limb_Muscle-18m-Endothelial|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.20e-04 | 173 | 9 | 2 | 6a7e4fa2d9d00f50decc89b535d8a68ec96de58a | |
| ToppCell | facs-Mammary_Gland-Mammary_Gland-18m-Endothelial-nan|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.20e-04 | 173 | 9 | 2 | 0b79e2a4fd19d524c24b69a6b524ffc6affdabe5 | |
| ToppCell | facs-Mammary_Gland-Mammary_Gland-18m-Endothelial-endothelial_cell|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.20e-04 | 173 | 9 | 2 | a2c1ef3f4d7e9f68fc77ee7c42a4727bdea5da94 | |
| ToppCell | facs-Mammary_Gland-Mammary_Gland-18m-Endothelial|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.20e-04 | 173 | 9 | 2 | 4830136f1f1976e00ac9af9062a531ac42533041 | |
| ToppCell | facs-Diaphragm-Limb_Muscle-18m-Endothelial-endothelial_cell|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.20e-04 | 173 | 9 | 2 | 2a5ea28c65dd4ee03ba3d0bfe0c819b1d583f8da | |
| ToppCell | (03)_Secretory-(0)_uninjured|(03)_Secretory / shred by cell type and Timepoint | 5.26e-04 | 174 | 9 | 2 | ebdddb5091afcc49ab533c890f260f709880c5f9 | |
| ToppCell | PND07-Epithelial-Epithelial_Airway-Neurosecretory|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 5.32e-04 | 175 | 9 | 2 | 19eda8b5d39dc93d79737ebdbeeba5ec0cb23c51 | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-0|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 5.50e-04 | 178 | 9 | 2 | be1d991c5a0a5be22f14f57d34ee1330f1a12963 | |
| ToppCell | Leuk-UTI-Lymphocyte-B-B_intermediate|Leuk-UTI / Disease, Lineage and Cell Type | 5.56e-04 | 179 | 9 | 2 | 01933f6fa94d7032ed403a6cae6985cafa820043 | |
| ToppCell | 390C-Lymphocytic-ILC-ILC-1|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 5.56e-04 | 179 | 9 | 2 | 3edcd1356e49b1f5514c585861999e079ca5e579 | |
| ToppCell | 390C-Lymphocytic-ILC-ILC-1|390C / Donor, Lineage, Cell class and subclass (all cells) | 5.56e-04 | 179 | 9 | 2 | e7045e27f0eb88f552b31c04b56d78e5ccd7a36c | |
| ToppCell | AT2_cells-Myositis-ILD_01|World / lung cells shred on cell class, cell subclass, sample id | 5.69e-04 | 181 | 9 | 2 | ed0ea67f0607073aedf153f8d1073b35e46127c3 | |
| ToppCell | facs-Heart-LA-18m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.75e-04 | 182 | 9 | 2 | 47b747722766dbcc6a73673e99ee5f938b82b890 | |
| ToppCell | 3'-GW_trimst-2-LargeIntestine-Endothelial-blood_vessel_EC-venous_capillary|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.94e-04 | 185 | 9 | 2 | a987dbf6adf533c5f8a0a8a465a6c8e67e0ffcc8 | |
| ToppCell | COVID-19-kidney-FLT1+PLVAP+EC|COVID-19 / Disease (COVID-19 only), tissue and cell type | 5.94e-04 | 185 | 9 | 2 | 673308ca0514a4d3629d61fe91e9d8fb31b72166 | |
| ToppCell | 5'-GW_trimst-1.5-SmallIntestine-Endothelial-blood_vessel_EC-Mature_venous_EC|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.00e-04 | 186 | 9 | 2 | e9d12f2fcd346fc8d00f7178324ea5997628df8a | |
| ToppCell | Control-Endothelial-Endothelial-Alv_Cap|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.07e-04 | 187 | 9 | 2 | ea9d34bcd3bd1f36745846309ede349773de501a | |
| ToppCell | 21-Trachea-Endothelial|Trachea / Age, Tissue, Lineage and Cell class | 6.26e-04 | 190 | 9 | 2 | bce09634acbc2cfd53666328e8aed8bf8835f845 | |
| ToppCell | 21-Trachea-Endothelial-Endothelial|Trachea / Age, Tissue, Lineage and Cell class | 6.26e-04 | 190 | 9 | 2 | 08437396a98ca9526f69c3a74bbf2929f3c68b8e | |
| ToppCell | (09)_Interm._secr.>cil.-(0)_Reference|(09)_Interm._secr.>cil. / shred by cell type by condition | 6.33e-04 | 191 | 9 | 2 | e63432718d62d39165ba8a66e14bb38c93907ffe | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Degenerative_Outer_Medullary_Collecting_Duct_Principal_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 6.33e-04 | 191 | 9 | 2 | 7235a4d1601c88a2c8af571a2c04ab56d32f1b9a | |
| ToppCell | IPF-Epithelial-Goblet|Epithelial / Disease state, Lineage and Cell class | 6.33e-04 | 191 | 9 | 2 | 267e1192aaec468c1a59eb24848b37e0e18cbc44 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Degenerative_Outer_Medullary_Collecting_Duct_Principal_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 6.33e-04 | 191 | 9 | 2 | 0a0719a0a49ae0099d61e22585ac74c10c24b4a2 | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell-Degenerative_Outer_Medullary_Collecting_Duct_Principal_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.39e-04 | 192 | 9 | 2 | 967122c53af25b8f19a8411b4553d764c8d51c4d | |
| ToppCell | kidney_cells-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.46e-04 | 193 | 9 | 2 | 371f4c98a599923fbe8382530b3eab05d873665a | |
| ToppCell | COPD-Epithelial-Goblet|Epithelial / Disease state, Lineage and Cell class | 6.53e-04 | 194 | 9 | 2 | 72a2e0cba171ab59aa176e91a59a54c562af0390 | |
| ToppCell | Healthy-B_intermediate|Healthy / disease group, cell group and cell class | 6.53e-04 | 194 | 9 | 2 | aabee48bf689367edae2079b4b90d253715f1097 | |
| ToppCell | 3'-Distal_airway-Epithelial-Epithelial_transtional-secretory-tracheobronchial_goblet_cell-Goblet_(subsegmental)|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.59e-04 | 195 | 9 | 2 | 576142b4e75457c0973051bccc4163bd624496af | |
| ToppCell | COVID-19-kidney-PLVAP+EC|kidney / Disease (COVID-19 only), tissue and cell type | 6.59e-04 | 195 | 9 | 2 | a436483fec137584611f86b7a498a4dc2aa19cd3 | |
| ToppCell | 3'-Distal_airway-Epithelial-Epithelial_transtional-secretory-tracheobronchial_goblet_cell|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.59e-04 | 195 | 9 | 2 | 8f151066ad3ebd9661ea0b733f03c2ce1518f9ad | |
| ToppCell | Epithelial_cells-Club_cells|Epithelial_cells / lung cells shred on cell class, cell subclass, sample id | 6.59e-04 | 195 | 9 | 2 | b758676abfc4e6930b696d270ecc0ea461b87a54 | |
| ToppCell | 3'-Distal_airway-Epithelial-Epithelial_transtional-secretory-tracheobronchial_goblet_cell-Goblet_(subsegmental)-Goblet_(subsegmental)_L.0.4.3.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.59e-04 | 195 | 9 | 2 | 2a9a36df1dbc4eac77a8ddbe939ec8a8d6c41464 | |
| ToppCell | Healthy-B_intermediate|World / disease group, cell group and cell class | 6.59e-04 | 195 | 9 | 2 | 9de79e0bdd9063ae65e5edb89cc3fe6f9a8173bc | |
| ToppCell | (05)_Secretory-(0)_Reference|(05)_Secretory / shred by cell type by condition | 6.66e-04 | 196 | 9 | 2 | 7cb79cf122852c971f2d6e8d1e2b26eade891e83 | |
| ToppCell | COVID-19-kidney-VWF+PLVAP+EC|kidney / Disease (COVID-19 only), tissue and cell type | 6.66e-04 | 196 | 9 | 2 | b71b197cb92117dd9efaa13de000841901cc4ca8 | |
| ToppCell | 5'-Parenchyma_lung-Endothelial-Blood_vessel_EC-capillary_endothelial_cell-EC_aerocyte_capillary-EC_aerocyte_capillary_L.2.0.1.2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.66e-04 | 196 | 9 | 2 | a53caedd0103bd162b3aee8ab87b4442a5e0338f | |
| ToppCell | (00)_Basal-(0)_Reference|(00)_Basal / shred by cell type by condition | 6.66e-04 | 196 | 9 | 2 | ba03530a20d7b29902721fd50df8d860557ddefa | |
| ToppCell | COVID-19-Epithelial-Club,_Basal_cells|Epithelial / Condition, Lineage and Cell class | 6.73e-04 | 197 | 9 | 2 | 78ed2810e5a765327e7a6da0ca5d4854bf7a0b6f | |
| ToppCell | normal_Lung-Epithelial_cells-Club|Epithelial_cells / Location, Cell class and cell subclass | 6.80e-04 | 198 | 9 | 2 | a9d0109ca05eb3e9c588f9677ec471dd5c092a75 | |
| ToppCell | Parenchymal-NucSeq-Epithelial-Epi_submucosal-gland|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 6.80e-04 | 198 | 9 | 2 | fab3135f03cf23a9f04f0eed543a9dc181f39f5f | |
| ToppCell | Bronchial_Brush-Epithelial-Club|Bronchial_Brush / Tissue, Lineage and Cell class of Lung Cells from 10X | 6.80e-04 | 198 | 9 | 2 | 61292a2b5aacb6080a679a31b70a211bdec59a3b | |
| ToppCell | Tracheal-10x3prime_v2-Endothelial-Endothelia_vascular-VE_alveolar_capillary_Car4_aerocyte|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 6.87e-04 | 199 | 9 | 2 | 1621ce2968f3100e4c39e0ef8293232a5d76c614 | |
| ToppCell | Bronchial_Brush-Epithelial-Club|Epithelial / Tissue, Lineage and Cell class of Lung Cells from 10X | 6.87e-04 | 199 | 9 | 2 | 53b87edccc89a3e8a6c5166472f9ef24fcba416c | |
| ToppCell | Sepsis-Leuk-UTI-Lymphocyte-B-B_intermediate|Leuk-UTI / Disease, condition lineage and cell class | 6.87e-04 | 199 | 9 | 2 | e3edf3bcb381dbcf0092bdc2ee93ba852d32af3f | |
| ToppCell | Bronchial_Biopsy-Epithelial|Bronchial_Biopsy / Tissue, Lineage and Cell class of Lung Cells from 10X | 6.87e-04 | 199 | 9 | 2 | ef5d8917c8d011184830a0b8197afc6266707b37 | |
| ToppCell | Biopsy_IPF-Epithelial-MUC5B+|Biopsy_IPF / Sample group, Lineage and Cell type | 6.93e-04 | 200 | 9 | 2 | f0a6747f6d37ec6d261bd649ac678c39cca5e4c8 | |
| ToppCell | Parenchymal-NucSeq-Epithelial-Epi_submucosal-gland-SMG_Duct|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 6.93e-04 | 200 | 9 | 2 | b992eeddee38e6fe3564e9b1850f6b20b89bf47d | |
| ToppCell | Sepsis-Int-URO-Lymphocyte-B-B_intermediate|Int-URO / Disease, condition lineage and cell class | 6.93e-04 | 200 | 9 | 2 | 221dd8d8851c47f2202ba848de3a041b17b1db3f | |
| Computational | Neighborhood of RBBP8 | 2.53e-04 | 213 | 7 | 3 | MORF_RBBP8 | |
| Computational | Genes upregulated in subsets of cells of a given type within various tumors | 4.39e-04 | 50 | 7 | 2 | GAVISH_3CA_MALIGNANT_METAPROGRAM_23_SECRETED_2 | |
| Computational | Membranal receptors. | 3.35e-03 | 517 | 7 | 3 | MODULE_64 | |
| Computational | Genes in the cancer module 12. | 3.39e-03 | 519 | 7 | 3 | MODULE_13 | |
| Computational | Neighborhood of LTK | 3.73e-03 | 147 | 7 | 2 | MORF_LTK | |
| Computational | Neighborhood of RAGE | 3.78e-03 | 148 | 7 | 2 | MORF_RAGE | |
| Computational | Genes in the cancer module 41. | 4.33e-03 | 566 | 7 | 3 | MODULE_41 | |
| Computational | Neighborhood of FANCG | 4.79e-03 | 167 | 7 | 2 | MORF_FANCG | |
| Drug | Butylparaben [94-26-8]; Up 200; 20.6uM; MCF7; HT_HG-U133A | 5.00e-05 | 195 | 9 | 3 | 5608_UP | |
| Drug | Idazoxan hydrochloride [79944-56-2]; Up 200; 16.6uM; MCF7; HT_HG-U133A | 5.00e-05 | 195 | 9 | 3 | 6465_UP | |
| Drug | Betonicine [515-25-3]; Up 200; 25.2uM; PC3; HT_HG-U133A | 5.08e-05 | 196 | 9 | 3 | 3745_UP | |
| Drug | Tropicamide [1508-75-4]; Up 200; 14uM; PC3; HT_HG-U133A | 5.24e-05 | 198 | 9 | 3 | 3722_UP | |
| Drug | Tiapride hydrochloride [51012-33-0]; Up 200; 11uM; MCF7; HT_HG-U133A | 5.31e-05 | 199 | 9 | 3 | 2292_UP | |
| Drug | butenal | 2.16e-03 | 180 | 9 | 2 | CID000020138 | |
| Drug | Alexidine dihydrochloride [22573-93-9]; Up 200; 6.8uM; PC3; HT_HG-U133A | 2.20e-03 | 182 | 9 | 2 | 3699_UP | |
| Drug | Azlocillin sodium salt [37091-65-9]; Up 200; 8.2uM; MCF7; HT_HG-U133A | 2.40e-03 | 190 | 9 | 2 | 3468_UP | |
| Drug | resveratrol; Up 200; 50uM; PC3; HG-U133A | 2.42e-03 | 191 | 9 | 2 | 662_UP | |
| Drug | Chlorprothixene hydrochloride [6469-93-8]; Up 200; 11.4uM; MCF7; HT_HG-U133A | 2.42e-03 | 191 | 9 | 2 | 2627_UP | |
| Drug | Antipyrine, 4-hydroxy [1672-63-5]; Up 200; 19.6uM; MCF7; HT_HG-U133A | 2.45e-03 | 192 | 9 | 2 | 4175_UP | |
| Drug | Megestrol acetate [595-33-5]; Up 200; 10.4uM; MCF7; HT_HG-U133A | 2.45e-03 | 192 | 9 | 2 | 5013_UP | |
| Drug | Cloperastine hydrochloride [14984-68-0]; Up 200; 11uM; MCF7; HT_HG-U133A | 2.47e-03 | 193 | 9 | 2 | 3608_UP | |
| Drug | Decamethonium bromide [541-22-0]; Up 200; 9.6uM; MCF7; HT_HG-U133A | 2.47e-03 | 193 | 9 | 2 | 4174_UP | |
| Drug | Benzocaine [94-09-7]; Up 200; 24.2uM; PC3; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 4224_UP | |
| Drug | Avermectin B1 [71751-41-2]; Down 200; 4.8uM; MCF7; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 6081_DN | |
| Drug | Acetylsalicylsalicylic acid [530-75-6]; Down 200; 13.4uM; HL60; HG-U133A | 2.50e-03 | 194 | 9 | 2 | 1377_DN | |
| Drug | Orphenadrine hydrochloride [341-69-5]; Up 200; 13uM; PC3; HT_HG-U133A | 2.50e-03 | 194 | 9 | 2 | 4537_UP | |
| Drug | Salsolinol hydrobromide [38221-21-5]; Up 200; 15.4uM; PC3; HT_HG-U133A | 2.53e-03 | 195 | 9 | 2 | 4232_UP | |
| Drug | LY 294002; Up 200; 0.1uM; MCF7; HT_HG-U133A | 2.53e-03 | 195 | 9 | 2 | 5576_UP | |
| Drug | Ofloxacin [82419-36-1]; Up 200; 11uM; PC3; HT_HG-U133A | 2.53e-03 | 195 | 9 | 2 | 7372_UP | |
| Drug | Ticlopidine hydrochloride [53885-35-1]; Down 200; 13.4uM; MCF7; HT_HG-U133A | 2.53e-03 | 195 | 9 | 2 | 4155_DN | |
| Drug | Cimetidine [51481-61-9]; Up 200; 15.8uM; PC3; HT_HG-U133A | 2.53e-03 | 195 | 9 | 2 | 4063_UP | |
| Drug | Furazolidone [67-45-8]; Down 200; 17.8uM; MCF7; HT_HG-U133A | 2.53e-03 | 195 | 9 | 2 | 3358_DN | |
| Drug | Nitrocaramiphen hydrochloride; Up 200; 10.8uM; MCF7; HT_HG-U133A | 2.55e-03 | 196 | 9 | 2 | 6504_UP | |
| Drug | Ivermectin [70288-86-7]; Down 200; 4.6uM; HL60; HG-U133A | 2.55e-03 | 196 | 9 | 2 | 1367_DN | |
| Drug | Lomefloxacin hydrochloride [98079-52-8]; Up 200; 10.4uM; MCF7; HT_HG-U133A | 2.55e-03 | 196 | 9 | 2 | 2310_UP | |
| Drug | Risperidone [106266-06-2]; Up 200; 9.8uM; MCF7; HT_HG-U133A | 2.55e-03 | 196 | 9 | 2 | 3508_UP | |
| Drug | Gossypol [303-45-7]; Down 200; 7.8uM; PC3; HT_HG-U133A | 2.55e-03 | 196 | 9 | 2 | 4296_DN | |
| Drug | 17-AAG; Down 200; 1uM; PC3; HG-U133A | 2.55e-03 | 196 | 9 | 2 | 432_DN | |
| Drug | Chlorpromazine hydrochloride [69-09-0]; Down 200; 11.2uM; HL60; HT_HG-U133A | 2.55e-03 | 196 | 9 | 2 | 1864_DN | |
| Drug | tetraethylenepentamine pentahydrochloride; Down 200; 100uM; HL60; HG-U133A | 2.55e-03 | 196 | 9 | 2 | 412_DN | |
| Drug | Diperodon hydrochloride [537-12-2]; Down 200; 9.2uM; HL60; HG-U133A | 2.55e-03 | 196 | 9 | 2 | 1575_DN | |
| Drug | Aminohippuric acid [61-78-9]; Up 200; 20.6uM; MCF7; HT_HG-U133A | 2.55e-03 | 196 | 9 | 2 | 6453_UP | |
| Drug | Chlorpropamide [94-20-2]; Up 200; 14.4uM; MCF7; HT_HG-U133A | 2.55e-03 | 196 | 9 | 2 | 3210_UP | |
| Drug | PHA-00745360 [351320-33-7]; Up 200; 1uM; PC3; HT_HG-U133A | 2.55e-03 | 196 | 9 | 2 | 3827_UP | |
| Drug | Etilefrine hydrochloride [534-87-2]; Up 200; 18.4uM; MCF7; HT_HG-U133A | 2.55e-03 | 196 | 9 | 2 | 4415_UP | |
| Drug | Flecainide acetate [54143-56-5]; Up 200; 8.4uM; PC3; HT_HG-U133A | 2.55e-03 | 196 | 9 | 2 | 3761_UP | |
| Drug | Sulpiride [15676-16-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 1467_UP | |
| Drug | Bumetanide [28395-03-1]; Down 200; 11uM; MCF7; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 7440_DN | |
| Drug | Pentolinium bitartrate [52-62-0]; Up 200; 7.4uM; MCF7; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 2305_UP | |
| Drug | Hymecromone [90-33-5]; Up 200; 22.8uM; HL60; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 3045_UP | |
| Drug | Succinylsulfathiazole [116-43-8]; Up 200; 11.2uM; MCF7; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 2821_UP | |
| Drug | sulindac; Down 200; 100uM; MCF7; HG-U133A | 2.58e-03 | 197 | 9 | 2 | 168_DN | |
| Drug | Amoxapine [14028-44-5]; Up 200; 12.8uM; MCF7; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 1513_UP | |
| Drug | WY-14643; Up 200; 100uM; PC3; HG-U133A | 2.58e-03 | 197 | 9 | 2 | 464_UP | |
| Drug | Erythromycin [114-07-8]; Up 200; 5.4uM; PC3; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 6729_UP | |
| Drug | Roxithromycin [80214-83-1]; Up 200; 4.8uM; PC3; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 4192_UP | |
| Drug | Cefotetan [69712-56-7]; Up 200; 7uM; MCF7; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 4116_UP | |
| Drug | CP-320650-01 [172079-28-6]; Down 200; 1uM; PC3; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 3825_DN | |
| Drug | Naloxone hydrochloride [357-08-4]; Up 200; 11uM; MCF7; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 1506_UP | |
| Drug | Hyoscyamine (L) [101-31-5]; Up 200; 13.8uM; PC3; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 5099_UP | |
| Drug | Carcinine [56897-53-1]; Up 200; 22uM; MCF7; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 3242_UP | |
| Drug | Ethamivan [304-84-7]; Up 200; 18uM; MCF7; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 2879_UP | |
| Drug | Trimethoprim [738-70-5]; Up 200; 13.8uM; MCF7; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 2307_UP | |
| Drug | Betulinic acid [472-15-1]; Up 200; 8.8uM; MCF7; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 4181_UP | |
| Drug | Rolipram [61413-54-5]; Up 200; 14.6uM; MCF7; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 6449_UP | |
| Drug | Phthalylsulfathiazole [85-73-4]; Up 200; 10uM; MCF7; HT_HG-U133A | 2.58e-03 | 197 | 9 | 2 | 5249_UP | |
| Drug | Glibenclamide [10238-21-8]; Up 200; 8uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 3163_UP | |
| Drug | Brompheniramine maleate [980-71-2]; Up 200; 9.2uM; PC3; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 4013_UP | |
| Drug | Lobelanidine hydrochloride [6112-86-3]; Up 200; 10.6uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 5500_UP | |
| Drug | CP-320650-01 [172079-28-6]; Down 200; 10uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 3905_DN | |
| Drug | Dipyrone [5907-38-0]; Up 200; 12uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 3929_UP | |
| Drug | Oxethazaine [126-27-2]; Up 200; 8.6uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 1484_UP | |
| Drug | Quinidine hydrochloride monohydrate [6151-40-2]; Up 200; 10.6uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 6267_UP | |
| Drug | LY294002; Up 200; 10uM; PC3; HG-U133A | 2.60e-03 | 198 | 9 | 2 | 461_UP | |
| Drug | Metyrapone [54-36-4]; Up 200; 17.6uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 6447_UP | |
| Drug | Prilocaine hydrochloride [1786-81-8]; Up 200; 15.6uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 3624_UP | |
| Drug | 17-AAG; Down 200; 0.1uM; MCF7; HG-U133A | 2.60e-03 | 198 | 9 | 2 | 221_DN | |
| Drug | Tracazolate hydrochloride [41094-88-6]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 4964_UP | |
| Drug | Nialamide [51-12-7]; Up 200; 13.4uM; PC3; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 3790_UP | |
| Drug | Nilutamide [63612-50-0]; Up 200; 12.6uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 6481_UP | |
| Drug | Practolol [6673-35-4]; Up 200; 15uM; PC3; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 4603_UP | |
| Drug | Tocopherol (R,S) [10191-41-0]; Up 200; 9.2uM; PC3; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 6616_UP | |
| Drug | Furaltadone hydrochloride [3759-92-0]; Up 200; 11uM; PC3; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 3756_UP | |
| Drug | Mephenesin [59-47-2]; Up 200; 22uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 2304_UP | |
| Drug | Azacyclonol [115-46-8]; Down 200; 15uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 5398_DN | |
| Drug | Nafcillin sodium salt monohydrate [7177-50-6]; Up 200; 8.8uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 3323_UP | |
| Drug | Etomidate [33125-97-2]; Up 200; 16.4uM; MCF7; HT_HG-U133A | 2.60e-03 | 198 | 9 | 2 | 3519_UP | |
| Drug | Ketotifen fumarate [34580-14-8]; Up 200; 9.4uM; MCF7; HT_HG-U133A | 2.63e-03 | 199 | 9 | 2 | 3200_UP |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| QVKCCGWVSFYNWTD | 146 | P27701 | |
| AWAIGKLYYENEQCW | 241 | Q13324 | |
| NCAVMFQGAWWYKNC | 256 | Q15485 | |
| WKWHGDNCYQFYKDS | 141 | Q8NC01 | |
| CQFCDKCYSWKKDWY | 796 | O95625 | |
| YKCDECDKVFNWWSQ | 181 | Q5SXM1 | |
| NWSVWCYVCDNEVQY | 111 | Q9Y5T5 | |
| CKFSSYEKYWCKWNN | 486 | P01833 | |
| YEKYWCKWNNTGCQA | 491 | P01833 | |
| YGVNAWKCWVQSKYA | 1066 | Q14202 |